SCHEMBL20103647

SCHEMBL20103647

CCOC(=O)C1CC=C(c2cncc(OC)n2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.39
CDK9 P50750 5/20 0.39
CCNT1 O60563 1/20 0.39
TSHR P16473 2/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
GAA P10253 1/20 0.37
PDK1 Q15118 1/20 0.36
RORC P51449 1/20 0.35
HSD17B10 Q99714 3/20 0.35
LIMK1 P53667 1/20 0.34
ALDH1A1 P00352 3/20 0.34
USP2 O75604 1/20 0.34
CYP1A2 P05177 1/20 0.34
HSP90AA1 P07900 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2542093 0.87 CDK9 (0.40) CDK9CCNT1TSHRALOX15MAPK1
SCHEMBL2542095 0.87 CDK9 (0.40) CDK9CCNT1TSHRALOX15MAPK1
SCHEMBL2538459 0.84 CDK9 (0.41) CDK9CCNT1TSHRALOX15MAPK1
SCHEMBL2538457 0.84 CDK9 (0.41) CDK9CCNT1TSHRALOX15MAPK1
SCHEMBL24461352 0.75 CDK9 (0.44) CDK9CCNT1TSHRALOX15MAPK1
SCHEMBL2517577 0.75 TSHR (0.47) CDK9CCNT1TSHRALOX15MAPK1
SCHEMBL2517575 0.75 TSHR (0.47) CDK9CCNT1TSHRALOX15MAPK1
SCHEMBL2540491 0.75 HTR1A (0.42) CDK9CCNT1TSHRALOX15MAPK1
SCHEMBL2540494 0.75 HTR1A (0.42) CDK9CCNT1TSHRALOX15MAPK1
SCHEMBL20103303 0.75 CDK9 (0.47) FFAR4CDK9CCNT1TSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10988433-B2 Cyclohexyl GPR40 agonists for the treatment of type II diabetes JANSSEN PHARMACEUTICA NV (BE) 2021-04-27 US disclosed
US-20200039914-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN RESEARCH & DEVELOPMENT, LLC 2020-02-06 US disclosed
WO-2018081047-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200039914-A1 CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES GPR119, GPR65, GPR55 FFAR4 22/4885CDK9 3507/4885CCNT1 1748/4885
US-10988433-B2 Cyclohexyl GPR40 agonists for the treatment of type II diabetes GPR119, GPR65, GPR55 FFAR4 22/4885CDK9 3507/4885CCNT1 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.